Personalis

Declining Sequencing Costs Will Unlock Precision Oncology Growth

AnalystHighTarget

Not Invested

Community Contributor

Published

09 Aug 25

AnalystHighTarget's Fair Value

US$9.00

3.6% undervalued

10 Sep

US$8.68

71.9%

25.6%

71.9%

25.6%

You can edit this narrative until Aug 9 9:18 PM. Then, changes will post as Updates.

Author's Valuation

US$93.6% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$9

3.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

26.21%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.37%

Calculation

US$37.64m

Earnings '28

51.89x

PE Ratio '28

US$1.95b

Market Cap '28

US$1.95b

Market Cap '28

175.37m

No. shares '28

US$11.14

Share Price '28

US$11.14 Share Price '28

Discounted to 2025 @ 7.37% p.a.

US$9.00

Fair Value '25